Skip to main content

Advertisement

Log in

A trial of high-dose ursodeoxycholic acid therapy in a liver transplant recipient

  • Letter to the Editor
  • Published:
Transplant International

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Calmus Y, Gane P, Rouger P, Poupon R (1990) Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology 11: 12–15

    PubMed  Google Scholar 

  2. Calmus Y, Guechot J, Podevin P, Bonnefis MT, Giboudeau J, Poupon R (1992) Differential effects of chenodeoxycholic and ursodeoxycholic acids on interleukin-1, interleukin-6 and tumor necrosis factor-α. production by monocytes. Hepatology 16: 719–723

    PubMed  Google Scholar 

  3. Dousset B, Conti F, Houssin, Calmus Y (1994) Acute vanishing bile duct syndrome after interferon therapy for recurrent HCV infection in liver-transplant recipients. N Engl J Med 330: 1160–1161

    Google Scholar 

  4. Friman S, Persson H, Scherstén T, Svanvik J, Karlberg I (1992) Adjuvant treatment with ursodeoxycholic acid reduces acute rejection after liver transplantation. Transplant Proc 24: 389–390

    PubMed  Google Scholar 

  5. Kato N, Yokosuka O, Hosoda K, Ito Y, Ohto M, Omata M (1993) Quantification of hepatitis C virus by competitive reverse transcription-polymerase chain reaction: increase of the virus in advanced liver disease. Hepatology 18: 16–20

    PubMed  Google Scholar 

  6. Kita Y, Beck Y, Teraoka S, Yokota K, Andoh Y, Nagao T, Gotoh M, Sakon M, Monden M (1996) Ursodeoxycholic acid therapy in recurrent or acquired genotype II hepatitis C virus infection after liver transplantation: a three-case report. Transplant Proc 28: 1701–1703

    PubMed  Google Scholar 

  7. Mohler M, Seipp S, Tox U, Stremmel W, Theilmann L, Goeser T (1996) Effect of ursodeoxycholic acid on HCV replication in subtyped chronic hepatitis C. Dig Dis Sci 41:1276–1277

    PubMed  Google Scholar 

  8. Pageaux GP, Blanc P, Perrigault PF, Navarro F, Fabre JM, Souche B, Domergue J, Larrey D, Michel H (1995) Failure of ursodeoxycholic acid to prevent acute cellular rejection after liver transplantation. J Hepatol 23: 119–122

    PubMed  Google Scholar 

  9. Poupon R, Chretien Y, Poupon RE, Ballet F, Calmus Y, Darnis F (1987) Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet 1:834–836

    PubMed  Google Scholar 

  10. Poupon RE, Chrétien Y, Poupon R, Paumgartner G (1993) Serum bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid therapy. Hepatology 17:599–604

    PubMed  Google Scholar 

  11. Takano S, Ito Y, Yokosuka O, Ohto M, Uchiumi K, Hirota K, Omata M (1994) A multicenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C. Hepatology 20: 558–564

    PubMed  Google Scholar 

  12. Yoshikawa M, Tsujii T Matsumura K, Yamao J, Matsumura Y, Kubo R, Fukui H, Ishizaka S (1992) Immunomodulatory effects of ursodeoxycholic acid on immune responses. Hepatology 16:358–364

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

About this article

Cite this article

Kita, Y., Yokota, K., Hirata, M. et al. A trial of high-dose ursodeoxycholic acid therapy in a liver transplant recipient. Transplant Int 10, 78–80 (1996). https://doi.org/10.1007/BF02044348

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02044348

Keywords

Navigation